

Software updates for ResAppDx to underpin growth

- **ResAppDx now has App Clip and Instant App capabilities – users can now access ResAppDx via website link, QR code or text message and do not need to download and install a standalone application**
- **Allows for enhanced integration with partners and a streamlined user experience**
- **New version can also detect undiagnosed chronic obstructive pulmonary disease (COPD)**
- **COPD accounts for 3m deaths globally and affects over 384m people worldwide – it is estimated that 80% of cases are undiagnosed**

Brisbane, Australia, 22 December 2020 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to report that it has released version 2.3 of its ResAppDx smartphone application on the Apple App Store and Google Play Store. The latest version of the application contains a number of advancements, including App Clip (iOS) and Instant App (Android) capabilities and the ability to detect chronic obstructive pulmonary disease (COPD).

ResAppDx is ResApp's acute respiratory disease diagnostic test that uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's inbuilt microphone. It is CE Marked in Europe and TGA approved for ARTG (Australian Register of Therapeutic Goods) listing in Australia as a Class IIa medical device.

ResAppDx is currently integrated into telehealth platforms via a software development kit (SDK) which incorporates ResAppDx directly into a telehealth provider's app, or via a link to a standalone ResAppDx app when the telehealth provider does not have a native Android or iOS app or is providing telehealth via voice-only telephone.

Importantly, ResAppDx 2.3 now supports App Clip (on iOS) and Instant App (on Android) functionality. App Clip and Instant App software was introduced to allow users to experience or utilise a specific part of a smartphone application, without downloading it entirely to a device.

Instead of installing the ResAppDx app to undertake a respiratory diagnostic test, users can now access ResAppDx instantly through a website link, QR code or text message received from a clinician or telehealth provider. Test results will then be sent directly to the clinician for review. This is a major development for ResApp and will allow for enhanced integration of ResAppDx with new and existing partners.



The company is currently working with existing partners to incorporate ResAppDx as an App Clip or Instant App into current offerings.

The company has also added functionality which allows ResAppDx to detect COPD. COPD is a chronic lung disease, characterised by long-term breathing problems and poor airflow due to airway obstruction. Main symptoms include shortness of breath and cough with sputum production. It is a progressive disease, typically worsening over time. COPD accounts for approximately 3m deaths globally per year and is the fourth leading cause of death. It impacts over 384m people worldwide and it is estimated that 80% of people with COPD are undiagnosed.

The research behind ResAppDx's COPD detection technology was recently published in the peer-reviewed journal, JMIR Formative Research. The paper, entitled "Diagnosing Chronic Obstructive Airway Disease on a Smartphone Using Patient-Reported Symptoms and Cough Analysis: Diagnostic Accuracy Study"ⁱⁱ describes the positive findings from the Breathe Easy clinical study (refer ASX announcement: 23 April 2019). In the study the ResAppDx COPD detection algorithm demonstrated high agreement with clinical diagnosis and rapidly detected COPD in participants presenting with or without other infective lung illnesses.

ResApp is confident that the added COPD screening functionality will provide clinicians with another useful tool in the acute setting, as patients who present with respiratory symptoms who suffer from COPD should be treated differently to patients without COPD.

CEO and Managing Director Dr Tony Keating said: *"The software updates in the latest version of ResAppDx will not only allow for increased use of ResAppDx amongst clinicians, but also provide a more seamless integration with our partners' technology platforms and a streamlined customer experience for users.*

"The App Clip and Instant App functionality is game changing for ResAppDx, as it will allow users to utilise the application without having to download and install a standalone application. We are already working with existing partners to progress integration and are confident that this will underpin our growing user base.

"As the digital healthcare space continues to grow, ResApp will continue to innovate and improve its ResAppDx and SleepCheck offerings to ensure our solutions are world leading. The company has a number of growth initiatives planned over the coming months and looks forward to providing regular updates to shareholders."

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine

ResApp Health Limited ABN 51 094 468 318

Level 12, 100 Creek St, Brisbane QLD 4000 Australia

T +61 7 3724 0035 E info@resapphealth.com.au W www.resapphealth.com.au



learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.

ⁱ <https://doi.org/10.2196/24587>